南财智讯1月30日电，科兴制药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 13500万元—17500万元，同比预增328.83%—455.89%；预计2025年全年归属于上市公司股东的扣除非 经常性损益的净利润为5000万元—7000万元，同比预增41.83%—98.56%。本期业绩变化的主要原因： 2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 ...

科兴制药公告，预计2025年年度实现归属于母公司所有者的净利润为1.35亿元至1.75亿元，同比增加 328.83%至455.89%。预计归属于母公司所有者的扣除非经常性损益的净利润为5000万元至7000万元， 同比增加41.83%至98.56%。上年同期，归属于母公司所有者的净利润为3148.09万元，归属于母公司所 有者的扣除非经常性损益的净利润为3525.43万元。本期业绩变化的主要原因为公司积极开拓海外市 场，实现了海外收入的强劲增长，推动公司营业收入持续增长。 ...

随着全国多地进入流感高发期，公众健康防护再次成为社会焦点。国家卫健委监测数据显示，流感活动水平持续攀升，尤其在儿童及青少年群体中检出 率更高，凸显了科学防治的紧迫性[1]。在这一背景下，早期、有效的抗病毒干预对于缩短病程、降低重症风险、遏制病毒传播同样至关重要。作为深耕 抗病毒领域多年的生物制药企业，科兴制药（688136.SH）始终以创新为驱动，为呼吸道病毒感染防治提供更多样、更便捷的解决方案。 一、 从"广谱"到"精准"：干扰素的抗病毒防线 流感由流感病毒引起，其快速复制和传播能力是导致疾病流行的关键。理想的抗病毒策略之一是尽早激活并强化人体自身的固有免疫防御。干扰素，正 是人体抵御病毒感染的第一道天然防线。当病毒入侵时，细胞会迅速产生干扰素，它通过激活一系列下游效应蛋白，在细胞间建立"抗病毒状态"，从而 抑制病毒的复制与扩散[2]。 人干扰素α1b是中国自主研发的I型干扰素，具有天然、广谱的抗病毒活性和相对温和的免疫调节特性。科兴制药是国内较早从事干扰素研发与生产的企 业，公司核心产品-注射用人干扰素α1b（商品名：赛若金 ）自上市以来，已在临床广泛应用三十载。 二、 赛若金 ：经典可靠的抗病毒"卫士" ...

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced fluctuations, with a recent decline of 2.06%, while the company shows a year-to-date increase of 11.34% in stock price, indicating mixed market sentiment towards its performance and potential [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, showing a significant year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has seen a net outflow of 8.37 million yuan from major funds, with significant buying and selling activity from large orders [1]. Dividend Distribution - Kexing Pharmaceutical has distributed a total of 51.54 million yuan in dividends since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the second-largest shareholder with 2.0621 million shares, a decrease of 1.6069 million shares from the previous period [3]. - Other significant changes in institutional holdings include an increase in shares held by Fortune Tianhui Growth Mixed A/B and a decrease in shares held by Fortune Precision Medical Flexible Allocation Mixed A [3].

Group 1 - The Hang Seng Technology Index increased by 1.93% and the Hang Seng Index rose by 1.32% [1] - Notable stock performances include: Zhaoyi Innovation up by 45.06%, Dali Group Holdings up by 13.35%, and Rongchang Bio up by 8.84% [1] - Declining stocks include: Times Angel down by 4.96%, Master Kong Holdings down by 4.18%, and CIMC Enric down by 3.72% [1]

Core Viewpoint - Erythropoietin (EPO) is a glycoprotein hormone crucial for red blood cell production, primarily secreted by the kidneys, with significant implications for treating various types of anemia, particularly in chronic kidney disease (CKD) patients [1][2][4]. Group 1: EPO Drug Overview - EPO is essential for stimulating red blood cell production and regulating oxygen supply in the body, with applications in treating renal anemia, chemotherapy-related anemia, anemia in premature infants, and perioperative red blood cell mobilization [4][5]. - The global prevalence of CKD has significantly increased, with 156 million cases reported in China in 2023, up from 75.42 million in 1990, highlighting the growing public health challenge [6][7]. Group 2: Market Dynamics - The Chinese EPO drug market is projected to decline from 30 billion yuan in 2024 to 31 billion yuan in 2025, before recovering to 37 billion yuan by 2030, with a compound annual growth rate (CAGR) of 3.6% from 2025 to 2030 [7][9]. - Economic factors and healthcare limitations have resulted in unmet needs for renal anemia and other related conditions, suggesting a rising demand for EPO as healthcare access improves [9]. Group 3: Competitive Landscape - The EPO market in China is concentrated, with the top three companies holding 56.1% market share in 2024, led by Sangamo Therapeutics with over 30% market share, followed by Kexing Pharmaceutical at 16.7% [10]. - As of 2025, there are 79 EPO products approved in China, with significant competition among domestic companies, although many remain focused on first-generation EPO products rather than advancing to second-generation long-acting formulations [10].

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The company plans to conduct foreign exchange derivative trading in 2026 to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a total trading limit not exceeding 75 million RMB or equivalent foreign currency [4][10]. - The trading will primarily utilize the company's own funds and will not involve raised funds [5][6]. - The company will employ simple and transparent foreign exchange derivative instruments, such as forward contracts and options, with a maximum duration of 12 months [6][8]. Group 2 - The company has approved the use of up to 150 million RMB of temporarily idle raised funds for cash management, focusing on safe and liquid investment products with a maturity of no more than 12 months [21][24]. - The investment aims to enhance the efficiency of raised fund usage while ensuring that it does not affect the ongoing projects funded by these raised funds [23][38]. - The company will strictly control risks associated with these investments and will not use the funds for speculative purposes [35][50]. Group 3 - The company plans to provide a maximum guarantee of 320 million RMB for its subsidiaries' bank loans in 2026, which will enhance financing efficiency [53][60]. - The guarantee is based on the current business situation and is expected to be within a controllable risk range [54][61]. - The company has no overdue guarantees or litigation-related guarantees, ensuring a stable financial position [62]. Group 4 - The company anticipates daily related transactions with specific affiliated companies, with a total expected amount not exceeding 18.5 million RMB for 2026 [67][70]. - These transactions are necessary for the company's normal business operations and are conducted at market prices to ensure fairness [75][76]. - The company has established contracts with related parties to ensure compliance and protect shareholder interests [73][74]. Group 5 - The company intends to apply for a financing limit of up to 300 million RMB from banks and financial institutions in 2026, using its own assets as collateral [78][79]. - This financing is aimed at meeting the operational funding needs of the company and its subsidiaries without adversely affecting business operations [80].

格隆汇1月4日丨科兴制药(688136.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份131.93万股，占公司目前总股本比例为0.66%，回购成交的最 高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18万元(不含交易佣金等费 用)。 ...

Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]